Inclusion Criteria:

- be ≥ 18 years of age with documented pathological diagnosis of H&N (head and neck)
cancer.

- planned to receive H&N region IMRT treatment in which the mean dose to the dermis in
the scalp risk zone (isodose plan) is estimated to be at least 20 Gy.

- have a palpable nuchal prominence (external occipital protuberance)

- have the ability to understand the informed consent document.

- be able to comply with protocol schedule.

- have a negative serum pregnancy test if a female of childbearing potential.

- consent to utilize medically acceptable methods of contraception throughout the study
if of childbearing potential.

- be treated with IMRT alone or with concurrent platinum based chemotherapy

- receive definitive treatment for oropharyngeal squamous cell carcinoma

Exclusion Criteria:

- with clinical or radiographic evidence of adenopathy to the high level V posterior
cervical nodes, post-auricular or occipital cervical nodal stations

- planned to receive H&N region treatment in which the mean dose to the dermis in the
scalp risk zone (isodose plan) is estimated to exceed 50Gy

- with underlying active untreated cardiac disease (e.g. arrhythmia)

- receiving concurrent chemotherapy other than single agent platinum based

- with generalized skin disorders that have required treatment within the past 6
months.

- with connective tissue disorders

- with unhealed wounds or scars in the study area

- with rashes, ulcerations, or poorly healed scars in the treatment area

- with a known allergy to norepinephrine

- with a known clinically significant abnormal ECG (electrocardiogram) within the past
6 months.

- taking MAO (monoamine oxidase) inhibitors or antidepressants of the triptyline or
imipramine types

- taking β-blockers

- with NCI-CTCAE Version 4.0 grade 2 or higher hypertension at the time of study entry.